Sotagliflozin, the most advanced dual SGLT1/SGLT2 inhibitor developed to date, encountered setbacks during phase III trials in patients with type 2 diabetes (T2D) and heart failure, largely due to financial challenges and disruptions caused by the COVID-19 pandemic [136]. The gene discussed is SLC5A2; the disease is heart failure.